
Premenstrual Syndrome Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
Description
Premenstrual Syndrome Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
The global premenstrual syndrome treatment market size reached US$ 1,346 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,683 Million by 2028, exhibiting a growth rate (CAGR) of 3.79% during 2022-2028.
Premenstrual syndrome (PMS) treatment refers to the therapeutic processes utilized for minimizing emotional, physical and psychological symptoms, such as bloating, breast tenderness, body pain, fatigue, mood fluctuations and anxiety, in women. PMS is commonly observed at the end of the luteal phase and dissipates with menstruation or shortly after. The treatment involves the use of antidepressants, analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), diuretics, ovarian suppression agents and hormonal contraceptives. These drugs are usually available over the counter (OTC) or are prescribed by a doctor. Novel PMS treatment drugs, such as topical gels, creams, capsules and suppositories, are manufactured using cannabidiol extracts for the management of mood imbalances, minimizing uterine cramps and facilitating muscle relaxation.
Premenstrual Syndrome Treatment Market Trends:
The increasing prevalence of PMS and premenstrual dysphoric disorder (PMDD) across the globe is one of the key factors driving the growth of the market. This can be attributed to the sedentary lifestyles and hectic schedules of the female working population. Moreover, rising awareness among the masses regarding available treatment alternatives for PMS and other related disorders is providing a thrust to the market growth. Pharmaceutical manufacturers are launching medications that have minimal side effects and aid in maintaining the appropriate pH balance in the body. Additionally, the widespread adoption of nutritional supplements manufactured using plant-based sources to provide relief from PMS is acting as another growth-inducing factor. These supplements contain the recommended amount of nutrients, such as calcium, magnesium, potassium and proteins, that aid in reducing fatigue and easing anxiety and depression. Healthcare organizations are also developing smartphone applications that periodically record physiological and emotional changes occurring in the body and send notification alerts as medication reminders. Other factors, including rising healthcare expenditure capacities of the consumers, along with extensive research and development (R&D) activities, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global premenstrual syndrome treatment market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug type, type and distribution channel.
Breakup by Drug Type:
Analgesics
Antidepressants
Oral Contraceptives and Ovarian Suppression Agents
Others
Breakup by Type:
Prescription
Over-the-Counter
Breakup by Distribution Channel:
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Stores
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy’s Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc. and SHIONOGI & Co. Ltd.
Key Questions Answered in This Report
1. What was the size of the global premenstrual syndrome treatment market in 2022?
2. What is the expected growth rate of the global premenstrual syndrome treatment market during 2023-2028?
3. What are the key factors driving the global premenstrual syndrome treatment market?
4. What has been the impact of COVID-19 on the global premenstrual syndrome treatment market?
5. What is the breakup of the global premenstrual syndrome treatment market based on the drug type?
6. What is the breakup of the global premenstrual syndrome treatment market based on the type?
7. What is the breakup of the global premenstrual syndrome treatment market based on the distribution channel?
8. What are the key regions in the global premenstrual syndrome treatment market?
9. Who are the key players/companies in the global premenstrual syndrome treatment market?
Table of Contents
141 Pages
- 1 Preface
- 2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
- 5 Global Premenstrual Syndrome Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
- 6 Market Breakup by Drug Type
- 6.1 Analgesics
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Antidepressants
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Oral Contraceptives and Ovarian Suppression Agents
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 7 Market Breakup by Type
- 7.1 Prescription
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Over-the-Counter
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 8 Market Breakup by Distribution Channel
- 8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Drug Stores and Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Online Stores
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
- 10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
- 11 Value Chain Analysis
- 12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
- 13 Price Analysis
- 14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 AbbVie Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 BASF SE
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Bayer AG
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Dr. Reddy’s Laboratories Ltd
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Eli Lilly and Company
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 GlaxoSmithKline Plc.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 H. Lundbeck A/S
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Pfizer Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 SHIONOGI & Co. Ltd.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.